AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78;IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)

AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

AALL06N1: A Study of Neurocognitive Function in Children Treated for ALL

AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

AALL08B1: The Classification of Acute Lymphoblastic Leukemia

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

AAML07P1: A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia

AAML1031: Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

ABTR01B1: Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors

ACCL0933: Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

ACCL0935: (SCUSF 0703) Prevention of Cancer/Treatment-Related Weight Loss in Children with Cancers Associated with a High Nutritional Risk

ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

ACNS02B3: Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

ACNS0331: Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial

ACNS0334: A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate

ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

AEWS07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

AHEP0731: Treatment of Children with All Stages of Hepatoblastoma

AHOD04B1: Hodgkin Disease Banking Study

ALTE05N1: Umbrella Long-term Follow-up Protocol

ANBL00B1: Neuroblastoma Biology Studies

ANBL00P3: Phase III randomized trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone

ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma

AOST06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens

AREN0321: Treatment of High Risk Renal Tumors

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age

ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)

ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab[IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma